Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
ACTIVE_NOT_RECRUITING
Status
Conditions
- ER+ Breast Cancer
- Ovarian Cancer
- Cervical Squamous Cell Carcinoma
- Pancreatic Adenocarcinoma
- Endometrial Cancer
- Renal Cell Carcinoma
- Urothelial Cancer
- Head and Neck Squamous Cell Carcinoma
- Mesothelioma
- Melanoma
- Hepatocellular Carcinoma
- Prostate Cancer
- NSCLC
- HER2-negative Breast Cancer
- Triple Negative Breast Cancer
- Bladder Cancer
- Colorectal Cancer Metastatic
- GastroEsophageal Cancer
- NSCL2 Gene Mutation
- Esophageal Cancer
Interventions
- COMBINATION_PRODUCT: Obinutuzumab, naptumomab estafenatox and durvalumab
- COMBINATION_PRODUCT: Naptumomab estafenatox and durvalumab
Sponsor
NeoTX Therapeutics Ltd.
Collaborators